Abstract
The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. This CTAs-restricted pattern of expression in human malignancies together with its potential immunogenic properties, has stirred the interest of many researchers to use CTAs as one of the ideal targets in cancer immunotherapy. To date, multiple studies have shown that CTAs-based vaccines can elicit clinical and immunological responses in different tumors, including colorectal cancer (CRC). This review details our current understanding of CTAs and CRC in regard to the expression and immunological responses as well as some of the critical hurdles in CTAs-based immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 1093-1104 |
| Number of pages | 12 |
| Journal | Immunotherapy |
| Volume | 10 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 1 Sep 2018 |
Fingerprint
Keywords
- cancer testis antigen
- colorectal cancer
- expression
- immune responses
- immunotherapy
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
Cite this
The potential immune-eliciting cancer testis antigens in colorectal cancer. / Chi Soh, Joanne Ern; Abu, Nadiah; A. Jamal, A. Rahman.
In: Immunotherapy, Vol. 10, No. 12, 01.09.2018, p. 1093-1104.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The potential immune-eliciting cancer testis antigens in colorectal cancer
AU - Chi Soh, Joanne Ern
AU - Abu, Nadiah
AU - A. Jamal, A. Rahman
PY - 2018/9/1
Y1 - 2018/9/1
N2 - The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. This CTAs-restricted pattern of expression in human malignancies together with its potential immunogenic properties, has stirred the interest of many researchers to use CTAs as one of the ideal targets in cancer immunotherapy. To date, multiple studies have shown that CTAs-based vaccines can elicit clinical and immunological responses in different tumors, including colorectal cancer (CRC). This review details our current understanding of CTAs and CRC in regard to the expression and immunological responses as well as some of the critical hurdles in CTAs-based immunotherapy.
AB - The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. This CTAs-restricted pattern of expression in human malignancies together with its potential immunogenic properties, has stirred the interest of many researchers to use CTAs as one of the ideal targets in cancer immunotherapy. To date, multiple studies have shown that CTAs-based vaccines can elicit clinical and immunological responses in different tumors, including colorectal cancer (CRC). This review details our current understanding of CTAs and CRC in regard to the expression and immunological responses as well as some of the critical hurdles in CTAs-based immunotherapy.
KW - cancer testis antigen
KW - colorectal cancer
KW - expression
KW - immune responses
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85052975814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052975814&partnerID=8YFLogxK
U2 - 10.2217/imt-2018-0044
DO - 10.2217/imt-2018-0044
M3 - Review article
C2 - 30185136
AN - SCOPUS:85052975814
VL - 10
SP - 1093
EP - 1104
JO - Immunotherapy
JF - Immunotherapy
SN - 1750-743X
IS - 12
ER -